84447
document
Multidose , live attenuated , cold-recombinant , trivalent influenza vaccine in infants and young children . Twenty-two healthy infants and children received either cold-recombinant , trivalent influenza vaccine or placebo in a three-dose vaccine trial . Most ( 82 % ) who received vaccine were seronegative to all three vaccine strains ( 10 ( 6 ) TCID50/dose each ) : A/Kawasaki/9/86 ( H1N1 ) , A/Los Angeles/2/87 ( H3N2 ) , and B/Yamagata/16/88 . Vaccine was administered intranasally at time 0 and 2 and 4 months later . The vaccine was well tolerated and immunogenic when administered in a multidose regimen . The first dose stimulated antibody to H1 , H3 , and B in 59 % , 94 % , and 35 % of vaccinees , respectively , by hemagglutination inhibition ( HAI ) or ELISA . After two doses of vaccine , 93 % , 93 % , and 80 % had antibody by HAI or ELISA to H1 , H3 , and B , respectively . Most vaccinees ( 67 % ) responded to all three viruses after two doses of vaccine . The third dose contributed little to the vaccine 's immunogenicity . Multidose trivalent influenza vaccine is safe and induces an immune response in most vaccinees after two doses .
84448
Intervention_Pharmacological
influenza vaccine
84449
Intervention_Pharmacological
cold-recombinant , trivalent influenza vaccine
84450
Intervention_Control
placebo
84451
Intervention_Pharmacological
A/Kawasaki/9/86 ( H1N1
84452
Intervention_Pharmacological
A/Los Angeles/2/87 ( H3N2 )
84453
Intervention_Pharmacological
B/Yamagata/16/88
84454
Outcome_Physical
well
84455
Outcome_Mental
tolerated
84456
Outcome_Physical
and
84457
Outcome_Other
immunogenic
84458
Outcome_Physical
H1 , H3 , and B
84459
Outcome_Other
vaccine 's immunogenicity
84460
Outcome_Physical
.
84461
Outcome_Mental
immune response
84462
Participant_Age
infants
84463
Participant_Age
young children
84464
Participant_Sample-size
Twenty-two
84465
Participant_Condition
healthy
84466
Participant_Age
infants and children